title: The risk of risk reduction: can postmarket surveillance pose more risk than benefit?
authors.affiliation: University of Minnesota; Baker & Daniels LLP, Indianapolis, Indiana, and Washington, DC; and MR3 Medical, LLC, USA.
authors.forename: Ralph F
authors.initials: RF
authors.lastname: Hall
mesh_terms: D000932:Antiemetics / Q000009:adverse effects; D003625:Data Collection; D017147:Defibrillators, Implantable / Q000009:adverse effects; D018795:Device Approval; D030881:Disclosure; D004319:Doxylamine / Q000009:adverse effects; D017277:Drug Approval / Q000379:methods; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004869:Equipment Safety; D005260:Female; D006801:Humans; D007880:Legislation, Drug / Q000639:trends; D008297:Male; D011247:Pregnancy; D011358:Product Surveillance, Postmarketing; D012308:Risk Management; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000932:Antiemetics; D004319:Doxylamine; D017367:Selective Serotonin Reuptake Inhibitors